Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 10/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.52 |
| ▸ | ECE1 | P42892 | 1/20 | 0.52 |
| ▸ | GLP1R | P43220 | 1/20 | 0.52 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.52 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375423 | 1.00 | NPBWR1 (0.56) | NPBWR1KISS1ROPRD1IL23RRXFP1 | |
| SCHEMBL30198266 | 0.97 | NPBWR1 (0.60) | NPBWR1IL23RRXFP1PTH1R | |
| SCHEMBL30874406 | 0.95 | NPBWR1 (0.57) | NPBWR1KISS1ROPRD1IL23RRXFP1 | |
| SCHEMBL29370686 | 0.94 | NPBWR1 (0.56) | NPBWR1KISS1ROPRD1IL23RRXFP1 | |
| SCHEMBL15849869 | 0.93 | NPBWR1 (0.55) | NPBWR1KISS1ROPRD1IL23RRXFP1 | |
| SCHEMBL30253514 | 0.93 | NPBWR1 (0.60) | NPBWR1IL23RRXFP1PRMT1 | |
| SCHEMBL31614451 | 0.92 | NPBWR1 (0.63) | NPBWR1IL23RRXFP1 | |
| SCHEMBL29396822 | 0.91 | NPBWR1 (0.61) | NPBWR1IL23RRXFP1PTH1R | |
| SCHEMBL2194373 | 0.90 | KISS1R (0.57) | NPBWR1KISS1RIL23R | |
| SCHEMBL31743243 | 0.90 | KISS1R (0.58) | NPBWR1KISS1RECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173086-A1 | PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES | EAGLE RESOLUTE INVESTMENT LLC | 2023-06-08 | — | — | US | disclosed |
| US-8541456-B2 | Roflumilast for the treatment of diabetes mellitus type 2 | TAKEDA GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-8017633-B2 | Administering [3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide; hypertension, hyperlipidemia, hyperuricemia, gout and hypercoagulability | NYCOMED GMBH (DE) | 2011-09-13 | — | — | US | disclosed |
| US-20080214625-A1 | Roflumilast for the Treatment of Diabetes Mellitus | KONINKLIJKE HILIPS ELECTRONICS, N.V. (NL) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214625-A1 | Roflumilast for the Treatment of Diabetes Mellitus | NOS3, PLAT, PTGIS | NPBWR1 1385/4885KISS1R 1133/4885OPRD1 2182/4885 |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | PPARD, PPARA, PPARG | NPBWR1 641/4885KISS1R 1372/4885OPRD1 1163/4885 |
| US-20230173086-A1 | PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES | VIP, DNPEP, CD74 | NPBWR1 763/4885KISS1R 3501/4885OPRD1 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.